The Belgian biotech startup Oncurious is launching a phase I/IIa trial for an antibody to fight a brain tumor which affects children.
Oncurious in Leuven (Belgium) was just launched last April as an emerging oncology company focused orphan drugs for the treatment of pediatric cancers.
It’s the most common pediatric malignant brain tumor, accounting for 20% of all brain tumors in children. In the EU and US around 400 new patients are diagnosed annually, with boys being affected twice as much.
In February, new research on the role of placental growth factor (PlGF) in certain cancers was published in Cell, based on pre-clinical research conducted by the Jain Lab at Massachusetts General Hospital at Harvard (Boston) and Peter Carmeliet’s team at the Vlaams Institute for Biotechnology (VIB) in Flanders.